Fatema Mbb Ch Abdulaal
Research Subjects
Fatema Mbb Ch Abdulaal has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Ali Mohamed
Intensive Care Department, Theodor Bilharz Institute, Giza, Egypt
2 shared publications - Mohammad Mbb Ch Ahmad
NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates
2 shared publications - Mohan Jose
NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates
2 shared publications - Nivedita Mbb Ch Nair
NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates
2 shared publications - Rami Msc Soliman
NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates
2 shared publications - Sabah Mbb Ch Ahmed
NMC Royal Hospital, Khalifa City, Abu Dhabi, United Arab Emirates
2 shared publications
Latest Publications
- Open Access
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e37806
Evaluating the potential mediating role of ADAMTS13 activity in the relationship between obesity and the severity of COVID-19: A retrospective cohort study
Obesity and low enzyme A disintegrin and metalloproteinase with thrombospondin type-1 motif-13 (ADAMTS13) activity have been linked to poor coronavirus disease 2019 (COVID-19). Given that obesity may influence ADAMTS13 activity, it is feasible; however, it remains unclear whether ADAMTS13 activity acts as a mediator between obesity and COVID-19 outcomes. We investigated the link between body mass index (BMI) and COVID-19 outcomes, using ADAMTS13 activity as a mediator. ADAMTS13 activity was measured in 86 hospitalized COVID-19 patients. BMI, ADAMTS13 activity, and COVID-19 outcomes were assessed. Obese patients had a high odds ratio for low ADAMTS13 levels. When different levels of ADAMTS13 activity were considered, the severity of COVID-19 in obese patients was 4.5 times that in the normal BMI group. Furthermore, increased coagulopathy indicators correlated with low ADAMTS13 activity. Patients with elevated ALT and AST levels showed a 3 to 4-fold increase in the chances of low ADAMTS13 activity (OR:3.19, 95% CI:1.22–8.90, P = .021; OR:2.17, 95% CI:0.91–5.27, P = .082, respectively). When ADAMTS13 activity was considered, obese patients had greater COVID-19 severity and slower viral clearance than those with normal BMI. Low ADAMTS13 activity and impaired liver function are associated with poor COVID-19 outcomes. These findings encourage researchers to use molecular component identification to study the effects of obesity on the von Willebrand factor (VWF)/ADAMTS13 axis, COVID-19 pathogenesis, and outcomes.
- 12 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (15) , e37806
Open AccessEvaluating the potential mediating role of ADAMTS13 activity in the relationship between obesity and the severity of COVID-19: A retrospective cohort study
Obesity and low enzyme A disintegrin and metalloproteinase with thrombospondin type-1 motif-13 (ADAMTS13) activity have been linked to poor coronavirus disease 2019 (COVID-19). Given that obesity may influence ADAMTS13 activity, it is feasible; however, it remains unclear whether ADAMTS13 activity acts as a mediator between obesity and COVID-19 outcomes. We investigated the link between body mass index (BMI) and COVID-19 outcomes, using ADAMTS13 activity as a mediator. ADAMTS13 activity was measured in 86 hospitalized COVID-19 patients. BMI, ADAMTS13 activity, and COVID-19 outcomes were assessed. Obese patients had a high odds ratio for low ADAMTS13 levels. When different levels of ADAMTS13 activity were considered, the severity of COVID-19 in obese patients was 4.5 times that in the normal BMI group. Furthermore, increased coagulopathy indicators correlated with low ADAMTS13 activity. Patients with elevated ALT and AST levels showed a 3 to 4-fold increase in the chances of low ADAMTS13 activity (OR:3.19, 95% CI:1.22–8.90, P = .021; OR:2.17, 95% CI:0.91–5.27, P = .082, respectively). When ADAMTS13 activity was considered, obese patients had greater COVID-19 severity and slower viral clearance than those with normal BMI. Low ADAMTS13 activity and impaired liver function are associated with poor COVID-19 outcomes. These findings encourage researchers to use molecular component identification to study the effects of obesity on the von Willebrand factor (VWF)/ADAMTS13 axis, COVID-19 pathogenesis, and outcomes.
- Open Access
- 1 January 2024
- Published by Discover STM Publishing Ltd. in Saudi Journal of Emergency Medicine
- Vol. 5 (1) , 1-S1
Unveiling the Diagnostic Landscape: Assessing the Rate of Positive Findings in Radiological Imaging by the Emergency Department - A Retrospective Study (December 2022 – February 2023).
Rationale: Diagnostic imaging is vital for accurate diagnoses and timely treatment in the Emergency Department (ED). This retrospective study aimed to assess the rate of positive findings in ED-ordered radiology scans at NMC Royal Hospital, UAE, and to identify potential areas of overutilization. Objectives: The study seeks to develop a tool for judging scan appropriateness, using the rate of positive findings as a metric to evaluate imaging appropriateness. Secondary objectives included evaluating factors influencing imaging outcomes and providing recommendations to enhance patient care, reduce costs, and optimize resource utilization in the ED. Methods: Between December 2022 and February 2023, 25,343 ED visits were recorded, with 6,633 patients underwent imaging. Samples of 100 were randomly selected for each modality, X-ray, ultra-sound, and CT scans, and 38 for MRI (due to limited data availability), totaling 338 samples. The study comprehensively analyzed patient clinical history, imaging requests, radiologist reports, and final diagnoses from the Electronic Medical Records (EMR) system. Only positive findings directly related to the symptoms presented by patients in the ED were considered, while incidental or non-relevant findings were excluded from the analysis. Results: Among the selected sample size, X-ray utilization was (4602)18.16%, CT (1507)5.95%, ultra-sound (486)1.92%, and MRI (38)0.15%, representing an overall utilization rate of 26.18% (FIGURE 1). The rates of positive findings were as follows: ultrasound showed the highest rate at (41)41%, followed by CT at (30)30%, MRI at (11)28.9%, and (28)X-ray at 28%. Overall, a rate of positive findings of 32.54% across all modalities was observed (FIGURE 2). Discussion: It is essential to note that the percentages of positive findings may vary depending on regional factors, patient demographics, and medical practices. Precise diagnostic imaging in the ED is crucial. Thorough and accurate documentation, which justifies the order of the imaging, along with clear communication and collaborative decision-making between ER physicians and radiologists, are essential. Seeking senior consultations for challenging cases and implementing quality assurance programs are suggested to enhance the diagnostic process. Conclusion: While the positive findings rate can serve as a tool for assessing scan appropriateness, it is crucial to note that judging appropriateness of scans should depend on adherence to international and local guidelines for scan indications. Implementing changes based on these findings enhances resource optimization in the ED.
- 1 January 2024
- Published by Discover STM Publishing Ltd. in Saudi Journal of Emergency Medicine
- Vol. 5 (1) , 1-S1
Open AccessUnveiling the Diagnostic Landscape: Assessing the Rate of Positive Findings in Radiological Imaging by the Emergency Department - A Retrospective Study (December 2022 – February 2023).
Rationale: Diagnostic imaging is vital for accurate diagnoses and timely treatment in the Emergency Department (ED). This retrospective study aimed to assess the rate of positive findings in ED-ordered radiology scans at NMC Royal Hospital, UAE, and to identify potential areas of overutilization. Objectives: The study seeks to develop a tool for judging scan appropriateness, using the rate of positive findings as a metric to evaluate imaging appropriateness. Secondary objectives included evaluating factors influencing imaging outcomes and providing recommendations to enhance patient care, reduce costs, and optimize resource utilization in the ED. Methods: Between December 2022 and February 2023, 25,343 ED visits were recorded, with 6,633 patients underwent imaging. Samples of 100 were randomly selected for each modality, X-ray, ultra-sound, and CT scans, and 38 for MRI (due to limited data availability), totaling 338 samples. The study comprehensively analyzed patient clinical history, imaging requests, radiologist reports, and final diagnoses from the Electronic Medical Records (EMR) system. Only positive findings directly related to the symptoms presented by patients in the ED were considered, while incidental or non-relevant findings were excluded from the analysis. Results: Among the selected sample size, X-ray utilization was (4602)18.16%, CT (1507)5.95%, ultra-sound (486)1.92%, and MRI (38)0.15%, representing an overall utilization rate of 26.18% (FIGURE 1). The rates of positive findings were as follows: ultrasound showed the highest rate at (41)41%, followed by CT at (30)30%, MRI at (11)28.9%, and (28)X-ray at 28%. Overall, a rate of positive findings of 32.54% across all modalities was observed (FIGURE 2). Discussion: It is essential to note that the percentages of positive findings may vary depending on regional factors, patient demographics, and medical practices. Precise diagnostic imaging in the ED is crucial. Thorough and accurate documentation, which justifies the order of the imaging, along with clear communication and collaborative decision-making between ER physicians and radiologists, are essential. Seeking senior consultations for challenging cases and implementing quality assurance programs are suggested to enhance the diagnostic process. Conclusion: While the positive findings rate can serve as a tool for assessing scan appropriateness, it is crucial to note that judging appropriateness of scans should depend on adherence to international and local guidelines for scan indications. Implementing changes based on these findings enhances resource optimization in the ED.
- Open Access
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e36037
Interleukin-6 and the determinants of severe COVID-19: A retrospective cohort study
Cytokines, notably interleukin-6 (IL-6), increase considerably in patients with severe corona virus disease 2019 (COVID-19). This vigorous immune response may cause end-organ failure or death; hence, measuring IL-6 in the context of patient characteristics may help predict outcomes and encourage early comprehensive therapy. This study investigated the association between serum IL-6 levels, COVID-19 severity, and demographic, clinical, and biochemical characteristics. COVID-19 inpatients in NMC hospitals were investigated between November 2020 and November 2021. Several patient variables related to serum IL-6 and COVID-19 severity have been examined. The study included 374 COVID-19 inpatients, 235 of whom had severe disease with a median age of 51. The elderly had an increased risk of severe COVID-19 (73.8%) compared with young adults (71%), with higher white blood cells, D-dimer, Lactate dehydrogenase, creatinine, ferritin, prothrombin time, Procalcitonin, and fibrinogen levels (P < .001). C-reactive protein, troponin, intensive care unit admission, disease severity score, and mortality were significantly associated with higher serum IL-6 levels (P = .05) in the univariate analysis, but this significance disappeared in the multivariate analysis. IL-6, along with other demographic and clinical variables affected COVID-19 severity. These characteristics may predict patients at risk of severe disease and assist in establishing early comprehensive disease outcome strategies. Large-scale clinical research is needed to emphasize IL-6 and COVID-19.
- 10 November 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (45) , e36037
Open AccessInterleukin-6 and the determinants of severe COVID-19: A retrospective cohort study
Cytokines, notably interleukin-6 (IL-6), increase considerably in patients with severe corona virus disease 2019 (COVID-19). This vigorous immune response may cause end-organ failure or death; hence, measuring IL-6 in the context of patient characteristics may help predict outcomes and encourage early comprehensive therapy. This study investigated the association between serum IL-6 levels, COVID-19 severity, and demographic, clinical, and biochemical characteristics. COVID-19 inpatients in NMC hospitals were investigated between November 2020 and November 2021. Several patient variables related to serum IL-6 and COVID-19 severity have been examined. The study included 374 COVID-19 inpatients, 235 of whom had severe disease with a median age of 51. The elderly had an increased risk of severe COVID-19 (73.8%) compared with young adults (71%), with higher white blood cells, D-dimer, Lactate dehydrogenase, creatinine, ferritin, prothrombin time, Procalcitonin, and fibrinogen levels (P < .001). C-reactive protein, troponin, intensive care unit admission, disease severity score, and mortality were significantly associated with higher serum IL-6 levels (P = .05) in the univariate analysis, but this significance disappeared in the multivariate analysis. IL-6, along with other demographic and clinical variables affected COVID-19 severity. These characteristics may predict patients at risk of severe disease and assist in establishing early comprehensive disease outcome strategies. Large-scale clinical research is needed to emphasize IL-6 and COVID-19.